Atractyloside A

Overview

Atractyloside A is an orally active inhibitor of the TLR4 / MyD88 / NF-κB signaling pathway and also an opener of the mitochondrial permeability transition pore ( MPTP ). Atractyloside A interferes with the activation of the TLR4/MyD88/NF-κB pathway, thereby inhibiting intestinal inflammatory responses. Atractyloside A reverses mucin synthesis impairment, improves intestinal barrier integrity, and restores homeostasis by altering the composition of the gut microbiota. Atractyloside A can be used in studies related to spleen deficiency diarrhea and myocardial injury.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cardiovascular Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Aquaporin | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > MyD88 | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Mitochondrial Metabolism

Product Information

• Catalog No.: HY-N0237
• CAS No.: 126054-77-1
• Molecular Formula: C21H36O10
• Molecular Weight: 448.50
• Purity: 98.11%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution
• Availability: In-stock

Source

Original product source